Radiotherapeutics remain in the deal-making frame
A radionuclide deal between Lantheus and Noria mirrors that done by Novartis and Sofie, among others.
Asco-GU – Clear blue water between Keytruda and kidney cancer rivals
Merck & Co/Eisai’s Clear study results look better than Bristol/Exelixis’s Checkmate-9ER, but the big loser could be Pfizer.
Esmo 2020 puts Opdivo and Cabometyx back in the game
Full data from the Checkmate-9ER trial suggest a new combo to match Merck & Co’s Keytruda plus Inlyta in first-line renal cancer.
Esmo 2020 preview – a kidney cancer showdown gets star billing
Though late-breakers rightfully seize much of the limelight at the Esmo congress, investors should look further afield too.
Contingent value is back in vogue
This week another takeover included a CVR element, confirming a trend that has been gaining traction over the past year.
